Trial · NCT06908993
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
NCT06908993, Phase 3, Recruiting, Intergroupe Francophone de Cancerologie Thoracique
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated. Trials, record NCT06908993. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06908993
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated
- NCT number
- NCT06908993
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 133 participants, estimated
- Lead sponsor
- Intergroupe Francophone de Cancerologie Thoracique
- Conditions
- Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation
- Interventions
- Tepotinib, Pemetrexed (Alimta), Vinorelbine, Gemcitabine alone, Docetaxel, Paclitaxel, Pembrolizumab, Nivolumab, Atezolizumab
- First posted
- 2025-04-03
- Last updated
- 2025-12-17
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-Free Survival (PFS) | About 36 months | Progression-free survival is calculated from the date of randomization until progression as defined by independent review comity according to RECIST 1.1 or death (whichever occurs first). |
| Secondary | Global Health Status Quality of life | 6 weeks after randomization | Quality of life will be assessed using the EORTC (European Organisation for Research and Treatment of Cancer) Quality of Life Questionnaire C30 with lung cancer module LC29 at baseline and week 6. A linear transformation will be applied to standardise the raw score to a 0-100 range (100=best possible QoL). A 10-point change will be considered clinically meaningful. |
| Secondary | Overall Survival | About 36 months | Overall survival is calculated from the date of randomization until death (for whatever reason). |
| Secondary | Second Progression-Free Survival (PFS2) | About 36 months | PFS2 is defined as the time from randomization to the date of progression of disease on first subsequent systemic anti-cancer therapy (as defined by the RECIST criteria v.1.1) (second progression), or death from any cause, whichever occurs first. |
| Secondary | Time to next treatment or death (TNT-D) | About 36 months | TNT-D is defined as the time from randomization to the date of first subsequent systemic anti-cancer therapy (as defined by the RECIST criteria v.1.1), or death from any cause, whichever occurs first. |
| Secondary | Objective Response Rate (ORR) | About 36 months | ORR is defined as the proportion of patients who have achieved a best overall response of complete response (CR) or partial response (PR) as determined by investigator review of radiographic disease assessments per RECIST v1.1. |
| Secondary | Duration of response (DOR) | About 36 months | DOR is defined as the time from the date of the first documented response (CR or PR) to the earliest date of disease progression, as determined by Investigator review of radiographic disease assessments per RECIST v1.1, or death due to any cause. |
| Secondary | Quality of life of patient | About 36 months | Quality of life will be assessed using the EORTC (European Organisation for Research and Treatment of Cancer) C30 with lung cancer module LC29 at baseline and week 6. For each scale in QLQ-C30 LC29, a linear transformation will be applied to standardise the raw score to a 0-100 range (100=best possible function or QoL for functional scales and highest symptom burden for symptom scales and symptom items). A 10-point change in an item or domain will be considered clinically meaningful. QoL will be defined as improved when a ≥10-point increase will be recorded for functioning scales and ≥10-point reduction for symptom domains. |
| Secondary | Observance of treatments | About 36 months | The number of cycles will be reported for each arm. The number of dose interruptions and dose modifications will be reported on the safety population. |
| Secondary | Safety and tolerability of treatments | About 36 months | Safety is measured by the frequency and the severity of adverse events, serious or not, at each patient visit and at each post treatment follow-up visit using the CTCAE Version 5.0. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06908993
GET https://conductscience.org/api/trials/v1/NCT06908993/registered